M2BE

Multiscale in Mechanical and Biological Engineering
Foto_grupo M2BE

The M2BE research group mainly focuses its activity on the development of new methodologies and multi-scale numerical technologies in the fields of Mechanical and Biological Engineering. The M2BE group aims to promote progress and innovation in mechanobiological research, collaborating with leading international partners and developing new projects that position the region as an agent of excellence in this field of research.

In this context, the main goal of the M2BE Group is to promote progress and innovation in mechanobiological research in a fundamental and applied way in the R&D&I chain, collaborating with agents of reference at an international level and developing new projects that position the region as an agent of excellence in this field of research. In particular, we continue working on the combination of different methodologies (computer simulation models, in-vitro experimentation and clinical validation), which result in the following lines of research:

  • Computational design of prostheses and implants for personalized treatments.
  • Tissue Engineering and Mechanobiology of bone regeneration and remodelling.
  • Mechano-chemical-cellular biology.
  • Mechanobiology of tumour metastasis.
  • Biomechanical modelling of lung fibrosis.

 

We are a reference group recognized by the Government of Aragon, composed of 22 researchers and two technicians for research support.

Projects

Individual and Collective Migration of Immune Cellular Systems

ICoMICS aims to develop a novel virtual simulation platform to investigate how therapeutic immune cells (TICs) detect, move and interact with cancer cells and the tumour microenvironment.
ERC , Horizon Europe

COMPUTER-AIDED EFFECTIVE FRACTURE RISK STRATIFICATION OF PATIENTS WITH VERTEBRAL METASTASES FOR PERSONALISED TREATMENT THROUGH ROBUST COMPUTATIONAL MODELS VALIDATED IN CLINICAL SETTINGS

METASTRA will propose new guidelines for the stratification and management of metastatic patients. METASTRA approach is expected to cut the uncertain diagnoses from the current 60% down to 20% of cases. This will reduce patient suffering, and allow cutting expenditure by 2.4B€/year.
Horizonte Europa

VAScularised Tumour Organoids on a chip with human placenta vessels as a preclinical model for anticancer therapies

VASTO Proof of Concept aims to develop and test an innovative microfluidic-based platform, which allows to evaluate the efficacy of different cell immunotherapy strategies against solid tumours.
Horizonte Europa , ERC

Completed projects (since 2020)

Project End year
PRIMAGE
TUMOR-ON-CHIP
CURABONE
MEC2BIO
TE4MM
CELLBIOPRINT